| Identification | Back Directory | [Name]
bruceoside A | [CAS]
63306-30-9 | [Synonyms]
bruceoside A
13,20-Epoxy-2-(β-D-glucopyranosyloxy)-11β,12α-dihydroxy-15β-[(3-methyl-1-oxo-2-butenyl)oxy]-3,16-dioxopicras-1-en-21-oic acid methyl ester
Picras-1-en-21-oic acid, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-11,12-dihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-3,16-dioxo-, methyl ester, (11β,12α,15β)-
(11beta,12alpha,15beta)-13,20-Epoxy-2-(beta-D-glucopyranosyloxy)-11,12-dihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-3,16-dioxo-picras-1-en-21-oic acid methyl ester | [Molecular Formula]
C32H42O16 | [MDL Number]
MFCD01704317 | [MOL File]
63306-30-9.mol | [Molecular Weight]
682.67 |
| Hazard Information | Back Directory | [Uses]
Bruceoside A, an abundant quassinoid glycoside in Fructus Bruceae, possesses anti-cancer activity[1]. | [Definition]
ChEBI: Bruceoside A is a triterpenoid saponin. | [in vivo]
Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin[1]. | Animal Model: | Male ICR mice weighing 25.0 ± 5.0 g[1]. | | Dosage: | 22.5 mg/kg. | | Administration: | Intragastrically administrated. | | Result: | Reached its highest levels in three hours with a half-life value of 3.99 h. |
| [References]
[1] Yuan Xu, et al. Pharmacokinetic study on bruceoside A revealed the potential role of quassinoid glycosides for the anticancer properties of Fructus Bruceae. J Pharm Biomed Anal. 2019 Jun 5;170:264-272. DOI:10.1016/j.jpba.2019.03.052 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|